© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake/File Photo
WASHINGTON (Reuters) – Illumina Inc (NASDAQ:) filed an appeal late on Monday against an order by the U.S. Federal Trade Commission, which is demanding that the company divest cancer diagnostic test maker Grail Inc because of concern that its ownership would stifle competition in the U.S. market for cancer tests.
This text was written byObserveDavid focuses on progress & momentum shares which might be fairly priced and more likely to...
This text was written byComply withLifescience investor centered on non-consensus long-short funding concepts. I deal with small to mid-cap biotechnology...
This text was written byObserveI'm centered on progress and dividend earnings. My private technique revolves round setting myself up for...
This text was written byObserveI'm a private investor specializing in equities and diversified portfolios. On this diversification, I wish to...
Operator Greetings, and welcome to Limoneira's Fourth Quarter Fiscal Yr 2025 Monetary Outcomes Convention Name. It's now my pleasure to...
This text was written byComply withFreelance Monetary Author | Investments | Markets | Private Finance | RetirementI create written content...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
